Hot Features
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, typ... Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0024 | 3.58208955224 | 0.067 | 0.0694 | 0.067 | 28000 | 0.06777857 | CS |
| 4 | 0.00322 | 4.86551828347 | 0.06618 | 0.0724 | 0.0602 | 9991 | 0.06769769 | CS |
| 12 | -0.00393 | -5.35933451521 | 0.07333 | 0.08784 | 0.0492 | 26426 | 0.07179528 | CS |
| 26 | -0.0052 | -6.97050938338 | 0.0746 | 0.098 | 0.0492 | 19414 | 0.07358558 | CS |
| 52 | 0.0394 | 131.333333333 | 0.03 | 0.2102 | 0.03 | 25540 | 0.08326804 | CS |
| 156 | -0.0029 | -4.01106500692 | 0.0723 | 0.2102 | 0.023 | 21353 | 0.06448839 | CS |
| 260 | -0.5591 | -88.9578361177 | 0.6285 | 0.6485 | 0.023 | 26985 | 0.15580296 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.